Klinikum der Universitaet Muenchen AöR
Verified site
Munich, Germany
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
Acute Myeloid Leukemia is a fast‑growing blood cancer that often affects older adults or people with other health problems, making them unable to receive strong, high‑dose chemotherapy. The trial tests a new medicine called IPN60340, which is a laboratory‑made protein that attaches to a specific target on cancer cells, given through an IV line. All participants also receive two standard drugs: the injectable medicine azacitidine, which helps cancer cells mature and die, and the oral pill venetoclax, which blocks a protein that cancer cells need to survive. For comparison, some participants receive a harmless fluid called placebo instead of the new protein while still taking the two standard drugs.
The purpose of the study is to find out whether adding the new protein to the usual drug combination improves treatment results. Participants are randomly assigned to one of the two groups and receive the assigned medicines in repeated cycles over several months, with regular clinic visits for infusions, pill dispensing, and injections. Blood tests and other simple checks are done at each visit to see how the disease is responding and to watch for any side effects.
Researchers will look at how many people achieve complete remission (no signs of leukemia in the blood), how long remission lasts, overall survival time, and whether patients can go long periods without needing blood or platelet transfusions (transfusion independence). They will also record any side effects and ask participants to fill out short questionnaires about their daily well‑being. This information helps determine if the new treatment offers a meaningful benefit over the standard approach.
The trial runs in 9 steps – from screening to follow-up. Each step says what happens and what the team monitors.
7 criteria
20 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Munich, Germany
Limoges, France
Nantes, France
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is an experimental, human‑engineered antibody that is given through an IV drip. It is designed to attach to a specific target called the butyrophilin‑3A receptor on certain immune cells. In this trial, researchers are testing whether adding this antibody to standard treatment can help the body fight newly diagnosed acute myeloid leukemia more effectively.
is a chemotherapy medicine that is injected under the skin. It works by changing the DNA inside leukemia cells, which can stop the cells from growing and help them die. In the study, azacitidine is part of the standard background therapy that all participants receive.
is a pill taken by mouth. It blocks a protein called BCL‑2 that many cancer cells use to avoid dying. By inhibiting this protein, venetoclax helps the body’s own mechanisms kill the leukemia cells. In the trial, it is also given to all participants as part of the standard background treatment alongside azacitidine.
This drug is given by IV infusion as a clear solution and is a human‑engineered IgG1 monoclonal antibody that targets the butyrophilin‑3A receptor on leukemia cells. It is an experimental orphan drug currently being studied in clinical trials for acute myeloid leukemia (AML). The antibody works by marking the cancer cells so the immune system can recognize and destroy them. It belongs to the class of monoclonal antibody immunotherapies.
Venetoclax is taken orally as a tablet, usually 400 mg per day, and is an approved medicine for AML and chronic lymphocytic leukemia. It is used in this study together with azacitidine to treat patients who cannot receive intensive chemotherapy. The drug blocks the BCL‑2 protein, which helps cancer cells survive, thereby allowing the cells to die. It is classified as a BCL‑2 inhibitor and a targeted anticancer therapy.
Azacitidine is administered by subcutaneous injection at a dose of 75 mg/m² and is an approved treatment for AML and related blood disorders. In the trial it is combined with venetoclax and the test drug for patients unsuitable for intensive chemotherapy. It works by inserting into DNA and interfering with the abnormal growth of cancer cells, helping them to die or stop dividing. This medication is a hypomethylating antineoplastic agent.
Saline is given intravenously as a sterile salt‑water solution and serves as the placebo in this study. It has no active therapeutic effect and is used only to compare the effects of the active drugs. The solution simply provides a neutral fluid for infusion. It is classified as an isotonic solution and a placebo.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.